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Amphetamine (AMPH) inhibits uptake and causes release of
dopamine (DA) from presynaptic terminals. AMPH can act on
both vesicular storage of DA and directly on the dopamine
transporter (DAT). To assess the relative importance of these
two processes, we have examined the releasing actions of
AMPH in mice with a genetic deletion of the DAT. The sequence
of actions of AMPH has been determined by following the real
time changes of DA in the extracellular fluid of intact tissue with
fast scan cyclic voltammetry. In striatal slices from wild-type
mice, AMPH causes a gradual (;30 min) increase in extracel-
lular DA, with a concomitant disappearance of the pool of DA
available for depolarization-evoked release. Conversely, in
slices from mice lacking the DAT, although a similar disappear-
ance of electrically stimulated DA release occurs, extracellular
DA does not increase. Similarly, microdialysis measurements of
DA after AMPH in freely moving animals show no change in
mice lacking the DAT, whereas it increases 10-fold in wild-type
mice. In contrast, redistribution of DA from vesicles to the
cytoplasm by the use of a reserpine-like compound, Ro4–1284,
does not increase extracellular DA in slices from wild-type
animals; however, subsequent addition of AMPH induces rapid
(,5 min) release of DA. Thus, the DAT is required for the
releasing action, but not the vesicle-depleting action, of AMPH
on DA neurons, and the latter represents the rate-limiting step
in the effects of AMPH. Furthermore, these findings suggest
that in the absence of pharmacological manipulation, such as
the use of amphetamine, endogenous cytoplasmic DA normally
does not reach sufficient concentrations to reverse the DAT.
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The effects of psychostimulants are thought to result from in-
creased extracellular dopamine (DA) concentrations in limbic
regions of the brain, including the striatum (Koob and Bloom,
1988; Self and Nestler, 1995; Wise, 1996). Some psychostimulants,
such as cocaine, increase extracellular DA by inhibiting the re-
uptake of released DA by the plasma membrane DA transporter
(DAT) (Heikkila et al., 1975; Horn, 1990; Amara and Kuhar,
1993; Giros and Caron, 1993). Others, including the amphet-
amines, cause release of DA from presynaptic nerve terminals in
addition to inhibiting reuptake (Heikkila et al., 1975; Seiden et
al., 1993). DA can be released by two mechanisms (Raiteri et al.,
1979): vesicular release, which is calcium and impulse-dependent,
and transporter-mediated release, which is impulse-independent
and has little calcium dependence (Hurd and Ungerstedt, 1989;
Pierce and Kalivas, 1997). DA release in response to AMPH
occurs by the second mechanism. This process has been called
reverse transport (Sulzer et al., 1995).
Several specific sites of action of AMPH on DA neurons have
been identified. AMPH can cross plasma membranes via li-
pophilic diffusion (Mack and Bonisch, 1979; Liang and Rutledge,
1982a; Zaczek et al., 1991a,b), and it is also a substrate for the
DAT (Liang and Rutledge, 1982a,b; Zaczek et al., 1991a,b; Sei-
den et al., 1993). Once inside the cells, AMPH can displace DA
from secretory vesicles into the neuronal cytoplasm (Sulzer and
Rayport, 1990; Floor et al., 1995; Floor and Meng, 1996), from
which DA can then be released into the extracellular space by
outward transport by the DAT. The relative importance of these
two processes, vesicular depletion and reverse transport, has
remained controversial. On the one hand, the exchange diffusion
or reverse transport model (Fischer and Cho, 1979; Liang and
Rutledge, 1982a,b; Burnette et al., 1996) proposes that AMPH
acts primarily at the plasma membrane transporter, which acts as
a mobile carrier with a binding site that allows DA transport from
one side of the membrane to the other. By acting as a substrate,
AMPH increases the number of inward-facing transporter bind-
ing sites and thus increases the rate of reverse transport. Consis-
tent with this mechanism, early work showed that the behavioral
effects of AMPH were independent of vesicular stores (Scheel-
Kruger, 1971). In contrast, the weak base or vesicle depletion
model (Sulzer and Rayport, 1990; Sulzer et al., 1992) proposes
that the action of AMPH arises primarily from its effects on
secretory vesicles. AMPH enters DA vesicles and causes displace-
ment of DA from vesicles into the cytoplasm by disruption of the
interior-acidic pH gradient. In this view, the elevated cytoplasmic
DA and altered concentration gradient of DA across the plasma
membrane causes reverse transport of DA, a process independent
of AMPH (Sulzer et al., 1995). The complexity of the actions of
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AMPH, which has led to the mutual exclusion of these two
proposed models, has hampered a satisfactory resolution of the
issue.
The recent availability of a genetically modified mouse in which
the DAT gene has been deleted, in combination with the electro-
chemical technique of fast-scan cyclic voltammetry which allows
real-time measurements of neurotransmitter release and uptake,
has provided information about the requirement of the DAT in
the action of AMPH (Giros et al., 1996). Here, we further
characterize the model to establish the relative contribution of
vesicular depletion and reverse transport to the DA-releasing
actions of AMPH. We now demonstrate that although vesicular
depletion is rate-limiting, both of these mechanisms are critical in
producing DA release by AMPH.
MATERIALS AND METHODS
Animals. Male C57BL/129SvJ wild-type mice (DAT 1/1) and their
littermates homozygous for DAT deletion (homozygote DAT knockout
mice or DAT 2/2), 2- to 4-months-old, were used in these experiments.
They were housed in an animal care facility at a temperature of 23°C with
a 12 hr light cycle and given food and water ad libitum. They were caged
with approximately three other littermates of the same sex. Homozygote
DAT knockout mice differ markedly from their wild-type littermates,
demonstrating a specific phenotype characterized by behavioral hyper-
activity and dwarfism (Giros et al., 1996; Bosse et al., 1997). Animal care
was in accordance with institutional guidelines.
Cyclic voltammetry. Carbon-fiber electrodes were prepared as de-
scribed previously (Kawagoe et al., 1993). A potentiostat (EI-400, Ens-
man Instrumentation, Bloomington, IN) was used for fast-scan cyclic
voltammetry. The electrode potential was linearly scanned from 2400 to
1000 mV and back to 2400 mV at 300 V/sec, repeated every 100 msec.
The peak oxidation current for DA was between 500 and 700 mV. Each
electrode was calibrated with 10 mM DA at the end of the experiment.
Mice were decapitated, and the brain was rapidly removed. Coronal
slices (400 mm thick) containing the striatum were prepared, placed in a
recording chamber, and superfused with an artificial cerebrospinal fluid
(Jones et al., 1995a,b). DA release was evoked by single-pulse stimula-
tions (350 mA, 4 msec) from a stimulating electrode placed 100–200 mm
away from the carbon-fiber electrode (Jones et al., 1995a,b). Electrodes
were placed in the dorsolateral portion of the caudate-putamen. Each
slice served as its own precondition control. Background-subtracted
cyclic voltammograms were constructed by subtracting the background
current obtained before release (15–50 nA) from the current measured
after release. In every reported case, DA was the substance detected and
was identified by its characteristic cyclic voltammogram. Data were
analyzed with one-way ANOVA using Systat software (Evanston, IL).
Microdialysis. Intracerebral microdialysis (Ungerstedt, 1984; Gainetdinov
et al., 1997) was performed using concentric microdialysis probes (2 mm
membrane length; cutoff 6000 Da; CMA-11, CMA/Microdialysis, Solna,
Sweden). Stereotaxic coordinates were slightly different to correct for the
marked size difference between wild-type and DAT 2/2 mice at 8–10
weeks (DAT 2/2 55% of control weight) (Bosse et al., 1997): anteriopos-
terior (AP) 0.0, dorsoventral (DV) 24.4, lateral (L) 2.5 for DAT 1/1 mice,
and AP 0.0, DV 23.2, L 1.8 for DAT 2/2, relative to bregma (Franklin and
Paxinos, 1996). The dialysis probes were perfused during implantation into
the brain and for 1 hr afterward with artificial cerebrospinal fluid (in mM):
Na 1 150, K 1 3.0, Ca 21 1.4, Mg 21 0.8, PO4
2 31.0, Cl 2 155 (ESA Inc.,
Bedford, MA), pH 7.3. One hour after the operation, animals were re-
turned to their home cages; 24 hr after surgery the dialysis probe was
perfused at 1.0 ml /min for 80 min before the experiment. Perfusate samples
were collected every 20 min. At least four predrug samples were collected
before AMPH was administered.
HPLC. Measurements of DA and DOPAC in microdialysis samples
were by HPLC with electrochemical detection (HPLC/EC) with a mi-
crobore column (5 mm particles, Unijet C18, 1 3 150 mm; BAS, West
Lafayette, IN) and electrochemically detected with a Unijet (3 mm)
electrode. The mobile phase contained 50 mM sodium citrate, 10 mM
NaH2PO4 , 0.5 mM octyl sodium sulfate, 0.1 mM EDTA, and 17% meth-
anol, at pH 3.5.
Drugs. D-AMPH, cocaine, sulpiride, pargyline, and nialamide were
from Sigma (St. Louis, MO), Ro4–1284 was a gift from Hoffmann-
LaRoche (Nutley, NJ), and tetrabenazine was from Fluka (Buchs,
Switzerland).
RESULTS
Effect of AMPH on stimulated and baseline DA
Baseline and stimulated release of DA in striatal brain slices were
monitored by cyclic voltammetry. Electrically stimulated release
was elicited by a single pulse of electrical current locally applied
at 5 min intervals. Figure 1 shows representative profiles of
stimulated and baseline DA release over a 50 min period as
AMPH (10 mM) was applied to slices from wild-type (DAT 1/1)
and homozygote DAT knockout (DAT 2/2) mice. In slices from
wild-type mice, baseline DA release began to increase ;10 min
after AMPH application, as seen by the rise in the recordings. At
the same time, the amount of electrically stimulated DA release
started to decrease, as seen by the decreasing peak heights of the
“spikes” of DA efflux observed at each stimulation. The current
changes were confirmed to be caused by increases in DA by
examination of the cyclic voltammograms collected during the
time the baseline was rising, at the plateau for the baseline
release, and also at the peak of the response for the stimulated
release (data not shown). After ;25 min of AMPH, a plateau of
baseline release was established between 3 and 10 mM DA, with
an average of 4.2 6 0.8 mM. By 25–35 min of AMPH exposure,
electrically stimulated DA release had disappeared completely.
Effect of AMPH on DA in slices from
DAT-deficient mice
Application of AMPH to slices from DAT 2/2 mice did not
change baseline DA overflow. A decrease in electrically stimu-
lated DA release commenced ;15 min after AMPH treatment,
and it was eliminated after 45–60 min (Fig. 1). Thus AMPH
entered the DA terminals and depleted vesicular stores, as evi-
denced by the elimination of stimulated release, but did not cause
release of DA into the extracellular space in the absence of the
DAT. The longer time course for vesicular depletion in homozy-
gote DAT knockout mice compared with the wild type is consis-
tent with AMPH entering the DAT 2/2 nerve terminals at a
reduced rate when only lipophilic diffusion occurs. In contrast,
AMPH can accumulate in terminals from wild-type mice by
diffusion plus efficient uptake through the DAT (Fischer and
Cho, 1979; Liang and Rutledge, 1982a,b; Zaczek et al., 1991a,b).
Modulation of effects of AMPH by sulpiride
Figure 2 shows the amount of electrically stimulated DA release
and baseline DA overflow measured in 5 min intervals in slices
from wild-type and homozygote DAT knockout mice, with and
without sulpiride. In the presence of 2 mM sulpiride, a D2 recep-
tor antagonist, electrically stimulated DA release was abolished
by AMPH, with an approximate 10 min delay in slices from
wild-type mice. This lengthening of the time course of AMPH by
the addition of sulpiride indicates that presynaptic autoreceptor
activation by baseline DA overflow played a role in decreasing
stimulated release in the slices from wild-type mice. Electrically
stimulated release in slices from homozygote DAT knockout
mice was not altered by sulpiride, as expected, because there was
no increase in extracellular DA by AMPH and thus autoreceptors
were not activated. However, baseline DA overflow in slices from
wild-type mice, elevated by AMPH as a result of reverse trans-
port, was unaltered by sulpiride, suggesting that under the present
conditions DAT-mediated transport is not altered by autorecep-
tor inhibition. This finding is consistent with results from other
laboratories (Kuczenski et al., 1990; Iravani and Kruk, 1995).
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Microdialysis measurements of AMPH action
The detection limit for cyclic voltammetry is ;25 nM, and small
changes in baseline extracellular levels of DA might not be
measurable by this method, whereas microdialysis is more than
one order of magnitude more sensitive (Westerink and Justice,
1991). In vivo microdialysis was used to monitor extracellular
levels of DA in the striatum of freely moving wild-type and
homozygote DAT knockout mice. The results of the microdialysis
experiment are shown in Figure 3. After intraperitoneal admin-
istration of 10 mg/kg AMPH, wild-type mice showed a signifi-
Figure 1. Effect of AMPH (10 mM) on DA efflux in
striatal slices from wild-type (DAT 1/1) and ho-
mozygote DAT knockout (DAT 2/2) mice. Current
was measured by cyclic voltammetry at microelec-
trodes implanted in the slices. Stimulated DA re-
lease was elicited by single electrical pulses applied
to the slice at the times indicated by small arrow-
heads. On the time scale shown, electrically stimu-
lated DA release events appear as sharp spikes.
Baseline release was monitored as any increase in
the current measured between stimulations that was
identified as DA. In the absence of pharmacological
or electrical intervention, baseline and electrically
stimulated DA recordings were stable for .3 hr.
Inset, Single-pulse stimulations in slices from a wild-
type and homozygote DAT knockout mouse with
the time scale expanded to show the time course of
the DA release and clearance. Filled circles are indi-
vidual measurements of the concentration of DA,
collected every 100 msec.
Figure 2. Effect of AMPH (10 mM) on stimu-
lated release and baseline overflow of DA in the
absence and presence of sulpiride (2 mM), a D2
autoreceptor antagonist. Stimulated DA re-
lease is measured by cyclic voltammetry as the
peak height of DA elicited by a single electrical
pulse, and baseline overflow is measured as the
average DA concentration change over a 5 min
period between stimulations. Filled bars are
wild-type data, and open bars are homozygote
DAT knockout data. AMPH (top) or AMPH 1
sulpiride (AMPH 1 SULP) (bottom) were
added to the slice 5 min before the first mea-
surements. Results are the mean 6 SEM of at
least four independent experiments. *Signifi-
cantly different from AMPH alone data ( p ,
0.05).
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cant, 8- to 10-fold increase in extracellular DA, whereas homozy-
gote DAT knockout mice did not show any significant change
(Fig. 3A). Note that the basal extracellular levels of DA in
homozygote DAT knockout mice are about five times higher than
in DAT 1/1 mice [predrug concentrations of DA in dialysates
were 55 6 15 fmol/20 ml (n 5 6) for DAT 1/1 and 234 6 84
fmol/20 ml (n 5 6) for DAT 2/2 mice]. These in vivo data
confirm the cyclic voltammetry findings, which demonstrate that
the DA-releasing actions of AMPH are dependent on the DAT.
After AMPH administration, dialysate levels of dihydroxyphe-
nylacetic acid (DOPAC) were decreased by ;50% in both the
wild-type and mutant mice (Fig. 3B). This is consistent with
AMPH entering nerve terminals and inhibiting monoamine oxi-
dase (MAO), one of the known actions of AMPH (Green and El
Haut, 1978; Miller et al., 1980). These data provide additional
evidence that AMPH enters the presynaptic terminal in signifi-
cant amounts by lipophilic diffusion, in the absence of the DAT.
Moreover, they indicate that differences in the actions of AMPH
in wild-type versus DAT 2/2 mice are not attributable to their
differential effects on MAO.
Effect of inhibition of vesicular transport
To independently examine vesicle depletion and its effect on
transport, a vesicular monoamine transporter type 2 (VMAT-2)
inhibitor, Ro4–1284, which rapidly depletes secretory vesicles
(Colzi et al., 1993; Filinger, 1994), was used to mimic this aspect
of AMPH action. Application of Ro4–1284 (10 mM) to slices from
wild-type mice resulted in a gradual reduction in electrically
stimulated DA release over ;30 min, with no accompanying
increase in baseline DA overflow (Fig. 4). Stimulated DA release
remained constant over a similar time interval with no added drug
(Jones et al., 1995b). Similar results were also obtained with
another short-acting VMAT-2 inhibitor, tetrabenazine (data not
shown). Reserpine was not investigated because its actions are
very slow (Callaway et al., 1989; Cadoni et al., 1995). After
Ro4–1284 caused the disappearance of electrically stimulated
DA in a slice from a wild-type mouse, 10 mM AMPH was applied
to the slice, and baseline DA overflow increased rapidly (Fig. 4).
The magnitude of overflow under these conditions was similar to
that induced over 30 min with AMPH alone, but the rate of
overflow was much faster and a plateau was reached in 5–10 min
(Fig. 5). From these findings, the relative time courses of AMPH
actions in a striatal slice were estimated to be 25 min for vesicle
depletion and 5 min for reverse transport.
Application of 10 mM Ro4–1284 or tetrabenazine caused a
gradual reduction and final disappearance of electrically stimu-
lated DA release in slices from homozygote DAT knockout mice
similar to that found in the wild type. However, the addition of
AMPH did not induce measurable baseline overflow of DA (Fig.
4). This further confirms the requirement for DAT in the releas-
ing action of AMPH.
Inhibition of MAO was monitored along with Ro4–1284-
mediated vesicle depletion to test whether degradation of cyto-
plasmic DA was the reason for the lack of baseline DA overflow
after Ro4–1284. Figure 5 shows that 10 mM pargyline, an MAO
inhibitor, did not have any effect on baseline DA overflow or
stimulated DA release during Ro4–1284 application. Nialamide
(10 mM), another MAO inhibitor, also had no effect (data not
shown). Furthermore, the addition of 2 mM sulpiride to slices
before Ro4–1284 did not significantly alter the disappearance of
stimulated DA release (Fig. 5), indicating that autoreceptor stim-
ulation did not play a major role in the decrease in electrically
stimulated DA release in this case.
To duplicate uptake inhibition, another important property of
AMPH, cocaine was used in combination with Ro4–1284. Co-
caine (10 mM) was applied before Ro4–1284 and did not change
the effects of Ro4–1284 (Fig. 6, top). This indicates that rapid
reuptake was not masking any Ro4–1284-induced baseline DA
overflow. Preadministration of cocaine to the slice, however, did
prevent the rapid AMPH-induced baseline overflow normally
found after Ro4–1284 application. This was expected because
cocaine is known to inhibit the releasing action of AMPH.
Figure 3. Effect of AMPH (10 mg/kg., i.p.) on extracellular DA and
DOPAC measured by microdialysis in the striatum of freely moving mice.
Open circles are data from wild-type mice (DAT 1/1), and filled circles
are data from homozygote DAT knockout mice (DAT 2/2). A, Extra-
cellular DA is increased 8- to 10-fold in wild-type mice after AMPH,
whereas there is no significant difference in DA levels after AMPH in
homozygotes. B, Extracellular DOPAC is decreased to approximately the
same degree in both wild-type and homozygote mice. Concentrations of
DOPAC in dialysates were 12.3 6 3.5 pmol/20 ml for DAT 1/1 and 5.3 6
1.8 pmol/20 ml for DAT 2/2 mice. Results are the mean 6 SEM of six
independent experiments.
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Finally, cocaine applied after Ro4–1284 and AMPH had the
effect of decreasing the plateau of baseline DA overflow (Fig. 6,
bottom). Thus, the plateau level of DA reached after AMPH was
maintained by continuous release of DA via reverse transport,
which can be antagonized by a transporter blocker.
DISCUSSION
It has long been recognized that AMPH exerts numerous actions
on DA nerve terminals (Seiden et al., 1993). The present results
illustrate the central importance of both depletion of DA from
secretory vesicles and reversal of DAT-mediated transport in the
releasing effects of AMPH. Although both effects are necessary
to induce DA release (termed overflow here to distinguish it from
electrically stimulated release), the vesicle-depleting action of
AMPH is the rate-limiting step. In addition, several other points
of controversy are resolved. For example, the results clearly dem-
onstrate that the plasma membrane DAT is absolutely required
for the overflow of DA into the extracellular space, but it is not
required for the depletion of vesicular DA by AMPH. Moreover,
when endogenous, releasable DA was mobilized from vesicles
into the cytoplasm, the resulting increased DA concentration
gradient across the plasma membrane was not sufficient to reverse
the DAT to a measurable degree. Release under these conditions
was observed only in the presence of AMPH.
The initial step in the action of AMPH on DA terminals is its
entry. As shown previously, this usually occurs via the DAT
(Liang and Rutledge, 1982a). Entry by its lipophilic diffusion
across the plasma membrane has been demonstrated only at
concentrations far above its Ki for DA transport inhibition (Liang
and Rutledge, 1982a). However, our data from homozygote DAT
knockout mice demonstrate that diffusional entry can occur at
lower concentrations, although it is less efficient. In striatal slices
from homozygote DAT knockout mice, AMPH (10 mM) induces
depletion of electrically stimulated DA release, but it requires a
longer time than in tissue that contains transporters. Moreover, in
homozygote DAT knockout mice, 10 mg/kg AMPH inhibits
Figure 4. Effect of a fast-acting reserpine-like drug,
Ro4–1284 (10 mM), and AMPH (10 mM) on stimu-
lated and baseline release of DA. Individual record-
ings of DA efflux measured by cyclic voltammetry in
striatal slices from wild-type (DAT 1/1) and ho-
mozygote DAT knockout mice (DAT 2/2). Drugs
were applied to slices at the times indicated by the
large arrows. Top, Single-pulse stimulations were ap-
plied to a slice from a wild-type mouse at the times
indicated by the small arrowheads. Inset, Cyclic voltam-
mograms, current (nA) versus potential (mV) plots,
recorded during postcalibration with authentic DA
(solid line) and during the plateau phase of the release
induced by AMPH ( filled circles), are plotted for
comparison. Bottom, Single-pulse stimulations were
applied to a slice from a homozygote DAT knockout
mouse at the times indicated by the small arrowheads.
Figure 5. Effect of pargyline (PARG, 10 mM, top), an MAO inhibitor, and
sulpiride (SULP, 2 mM, bottom), a D2 autoreceptor antagonist, on the
effects of Ro4–1284 followed by AMPH in slices from wild-type mice.
Stimulated DA release is measured by cyclic voltammetry as the peak
height of DA elicited by single electrical pulses, and baseline overflow is
measured as the average DA concentration change over a 5 min period
between stimulations. PARG or SULP was added to the slice 10 min
before the first measurements. Results are the mean 6 SEM of at least
four independent experiments.
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MAO, as evidenced by a decrease in extracellular DOPAC mea-
sured by microdialysis, in an manner equivalent to that found in
wild-type animals. This provides further evidence that AMPH
can access intracellular compartments in the absence of the DAT.
Once inside the cell, AMPH can deplete vesicles of releasable
DA. This action, manifested as a decrease in electrically stimu-
lated release, is also found with the VMAT-2 inhibitors tested.
Although the pool of vesicular DA released by electrical stimu-
lation may comprise only a small fraction of the tissue content of
DA, this vesicular DA is of high significance, because it repre-
sents the most physiologically active DA. The actions of AMPH
and the reserpine-like compounds differ, however, in that only
AMPH induces an increase in baseline overflow that accompa-
nies the decrease in electrically stimulated release. We infer that
the DA displaced from the vesicles by Ro4–1284 is in the cyto-
plasm because it is not detected in the extracellular fluid. Thus,
the increased concentration gradient across the plasma mem-
brane caused by accumulation of free cytosolic DA f rom vesicles
is insufficient to reverse transport at the levels achieved in this
work, in contrast to previous proposals (Sulzer et al., 1993, 1995).
The DAT operates on an electrochemical gradient in which the
concentrations of substrate, sodium, and chloride, and membrane
potential are all important. DAT-mediated transport can be re-
versed if the cytoplasmic concentrations of substrate are manip-
ulated artificially, as shown by numerous in vitro studies (Eshle-
man et al., 1993; Pifl et al., 1995; Sulzer et al., 1995) or if the
normal ionic gradients are altered (Eshleman et al., 1993). How-
ever, our data show that the movement of the endogenous, re-
leasable vesicular pool of DA to the cytoplasm of DA nerve
terminals does not provide a sufficient concentration gradient to
reverse DAT-mediated transport.
AMPH addition to a slice depleted of releasable vesicular DA
leads to a rapid reversal of transport, further supporting our
inference that it is cytoplasmic. Apparently, an ongoing supply of
DA from the cytoplasm is supplied to the extracellular space via
the DAT, because when cocaine is added to the slice after
AMPH, the extracellular levels of DA drop. This reverse trans-
port of DA caused by AMPH is consistent with a recently
proposed mechanism for the norepinephrine transporter (Bur-
nette et al., 1996), in which any substrate added to the outside of
the cell will cause the allosteric translocation of the transporter to
the inside of the cell. Such an inward-facing transporter is avail-
able to transport free cytosolic substrate to the outside of the cell.
The probability of outward-directed transport is a function of the
concentration of an external transportable species, AMPH in this
case. The probability of reverse transport is lowered by blocking
access to the transporter, as demonstrated by the effects of co-
caine. This model is essentially the same as the “exchange diffu-
sion model” proposed by Fischer and Cho (1979). New evidence,
however, has demonstrated that the transporter can operate in a
channel-like mode, in which a pore is opened through the plasma
membrane (Sonders and Amara, 1996; Sonders et al., 1997). The
exact relationship between these properties, substrate binding,
inward transport, and reverse transport, has yet to be elucidated.
The times required for vesicular depletion and reverse trans-
port were measured to be ;25 min and 5 min, respectively. The
total time to induce a plateau level of DA overflow in an un-
treated slice was ;30 min, which is consistent with the time
course of AMPH-induced DA overflow in vivo as measured by
microdialysis (Fig. 3A). AMPH-induced depletion of DA from
synaptic vesicles can arise from inhibition of monoamine uptake
into vesicles through the VMAT-2 followed by leakage from the
vesicles (Knepper et al., 1988; Schuldiner et al., 1993; Peter et al.,
1994; Floor et al., 1995; Erickson et al., 1996), or by alkalinization
of the interior of vesicles (Sulzer and Rayport, 1990; Sulzer et al.,
1992; Schuldiner et al., 1993). The 30 min time course may be
required either to accumulate sufficient AMPH for vesicle deple-
tion or for the vesicles to “leak” out the stored DA. The rate of
reverse transport that follows AMPH after vesicle depletion with
reserpine-like drugs is consistent with the rates reported for efflux
of preloaded DA from COS7 cells (which do not have secretory
vesicles) transfected with the norepinephrine transporter (Bur-
nette et al., 1996).
There is an extensive literature regarding whether AMPH
releases cytoplasmic or vesicular DA (for review, see Seiden et al.,
1993). Pretreatment of animals with reserpine, a vesicular DA
depleter, does not abolish all of the DA release elicited by
AMPH. Subsequent treatment with a-methyl-p-tyrosine
(aMPT), a DA synthesis inhibitor, does abolish DA release
elicited by AMPH (Butcher et al., 1988, Callaway et al., 1989). In
addition, DA-mediated, AMPH-induced behaviors are not
blocked by reserpine (Creese and Iverson, 1975). These experi-
ments have been interpreted as meaning that AMPH primarily
releases DA from the newly synthesized, cytoplasmic pool of DA.
The present results and others (Chiueh and Moore, 1975; Liang
and Rutledge, 1982b; Parker and Cubeddu, 1986a,b; Cadoni et
al., 1995) suggest a different interpretation, one that includes two
separate, equally important aspects of DA release by AMPH. The
first is reverse transport by the DAT, which will cause the release
of any DA from the cytoplasm of the nerve terminal; the second
Figure 6. Effect of cocaine (COC, 10 mM) on the effects of Ro4–1284
followed by AMPH in slices from wild-type mice. Top, Cocaine was
added 10 min before the first measurements were made. Bottom, Cocaine
was added 15 min after AMPH. Results are the mean 6 SEM of at least
four independent experiments. *Significantly different from wild-type
values without cocaine ( p , 0.05).
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is the slower displacement of vesicular DA to the cytoplasm,
followed by release via reverse transport. This conclusion is
supported by the finding that in the presence of AMPH alone,
electrically stimulated release disappears within the same time
frame that baseline overflow appears (Fig. 1). This effect is
altered only slightly by the addition of autoreceptor antagonists,
since autoreceptors might be expected to decrease electrically
stimulated release as extracellular DA increases (Fig. 2). In ad-
dition, the finding that AMPH causes the same amount of DA
overflow before or after the movement of the readily releasable
vesicular stores of DA to the cytoplasm, albeit on different time
scales (Fig. 4), suggests that the vesicular pool is the major
supplier of DA for the releasing action of AMPH, and that the
time frame of DA appearance in the extracellular space is de-
pendent on vesicle depletion.
The observation that DOPAC levels are decreased to a similar
extent after AMPH in both wild-type and DAT knockout ani-
mals provides evidence for another action of AMPH, MAO
inhibition. Other hypotheses have been proposed to explain the
DOPAC decrease such as the removal of a major MAO substrate,
newly synthesized DA, by AMPH (Zetterstrom et al., 1988).
However, the results with homozygote DAT knockout animals
show that DOPAC was decreased even when cytoplasmic DA was
not released into the extracellular space, and when levels of
cytoplasmic DA had probably increased significantly. Under these
conditions, MAO inhibition by pargyline had no effect on the
cytoplasmic DA generated by VMAT-2 inhibitors, suggesting
that cytoplasmic dopamine can persist at least for the time of the
experiments before outward transport induced by AMPH.
In conclusion, we have demonstrated that both the vesicle
depletion and the reverse transport caused by AMPH are impor-
tant in its DA-releasing effects. We have shown that the time
course of reverse transport is much faster than that of vesicle
depletion (5 vs 25 min). In addition, we have demonstrated that
when the endogenous, releasable pool of DA is displaced into the
cytoplasm, it does not produce a concentration gradient across
the plasma membrane large enough for outward transport by the
DAT, and the presence of AMPH is required to catalyze this
effect.
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